MX2022001149A - Moduladores del receptor de estrógeno para el tratamiento de mutantes. - Google Patents
Moduladores del receptor de estrógeno para el tratamiento de mutantes.Info
- Publication number
- MX2022001149A MX2022001149A MX2022001149A MX2022001149A MX2022001149A MX 2022001149 A MX2022001149 A MX 2022001149A MX 2022001149 A MX2022001149 A MX 2022001149A MX 2022001149 A MX2022001149 A MX 2022001149A MX 2022001149 A MX2022001149 A MX 2022001149A
- Authority
- MX
- Mexico
- Prior art keywords
- estrogen receptor
- treating
- mutants
- receptor modulators
- breast cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente descripción se describen usos y métodos que incluyen una cantidad eficaz del Compuesto A (es decir ácido (E)-3-(4-((1R,3R)-2-(biciclo[1.1.1]pen-tan-1-il)-3-metil-2,3,4,9- tetrahidro-1H-pirido[3,4-b]indol-1-il)-3,5-difluorofenil)acrílico ), o una sal farmacéuticamente aceptable de este, para tratar el cáncer de mama en un sujeto que lo necesita, en donde el cáncer de mama tiene al menos una mutación puntual en el receptor de estrógeno 1 (ESR1) que codifica el receptor de estrógeno alfa (ERa), tal como Y537S o L536P.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962883395P | 2019-08-06 | 2019-08-06 | |
US202063009746P | 2020-04-14 | 2020-04-14 | |
PCT/US2020/044884 WO2021026153A1 (en) | 2019-08-06 | 2020-08-04 | Estrogen receptor modulators for treating mutants |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001149A true MX2022001149A (es) | 2022-04-06 |
Family
ID=74499460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001149A MX2022001149A (es) | 2019-08-06 | 2020-08-04 | Moduladores del receptor de estrógeno para el tratamiento de mutantes. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11278532B2 (es) |
EP (1) | EP3993787A4 (es) |
JP (1) | JP2022543832A (es) |
KR (1) | KR20220044528A (es) |
CN (1) | CN114269342A (es) |
AU (1) | AU2020326691A1 (es) |
BR (1) | BR112022002138A2 (es) |
CA (1) | CA3148221A1 (es) |
IL (1) | IL290280A (es) |
MX (1) | MX2022001149A (es) |
TW (1) | TW202120084A (es) |
WO (1) | WO2021026153A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4267578A1 (en) | 2020-12-23 | 2023-11-01 | Recurium IP Holdings, LLC | Estrogen receptor modulators |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT75522A (en) | 1994-03-11 | 1997-05-28 | Lilly Co Eli | Indole-, pyrido-indole-, indolo-quinoline- and benzo-pyrido-indole-derivatives, method for treating 5ht2b receptor related conditions, pharmaceutical compositions containing them |
GB9604996D0 (en) | 1996-03-08 | 1996-05-08 | Black James Foundation | Benzodiazonine derivatives |
EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
JP2005508968A (ja) | 2001-10-19 | 2005-04-07 | トランス テック ファーマ,インコーポレイテッド | PTP阻害剤としてのβ−カルボリン誘導体 |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
JP2008508356A (ja) | 2004-08-02 | 2008-03-21 | スミスクライン ビーチャム コーポレーション | Hpv感染に有用な化合物 |
WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
EP2037905B1 (en) | 2006-06-23 | 2013-05-01 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
US20100158858A1 (en) | 2007-04-13 | 2010-06-24 | Liangxian Cao | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
DE102007028515A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
CA2785790A1 (en) | 2010-01-15 | 2011-07-21 | Merck Sharp & Dohme Corp. | Oxadiazole beta carboline derivatives as antidiabetic compounds |
US20130172320A1 (en) | 2010-02-18 | 2013-07-04 | Sarvajit Chakravarty | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
CN102432608B (zh) | 2011-11-01 | 2013-04-17 | 浙江大学 | 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法 |
EA029559B1 (ru) | 2011-12-14 | 2018-04-30 | Серагон Фармасьютикалс, Инк. | Фторированные модуляторы рецепторов эстрогенов и их применение |
BR112014012628B8 (pt) | 2011-12-31 | 2023-01-17 | Beigene Ltd | Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp |
CN104220426B (zh) | 2012-03-20 | 2017-03-01 | 塞拉根制药公司 | 雌激素受体调节剂及其用途 |
EP3733170A1 (en) | 2012-07-13 | 2020-11-04 | Oncternal Therapeutics, Inc. | A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms) |
SI2958907T1 (en) | 2013-02-19 | 2018-05-31 | Novartis Ag | Benzothiophene derivatives and their compositions as selective estrogen receptor antagonists |
BR112015022566A2 (pt) | 2013-03-14 | 2017-07-18 | Seragon Pharmaceuticals Inc | composto e composição farmacêutica |
ES2654161T3 (es) | 2013-05-28 | 2018-02-12 | Astrazeneca Ab | Compuestos químicos |
KR20160085915A (ko) | 2013-12-06 | 2016-07-18 | 에프. 호프만-라 로슈 아게 | 국소 진행성 또는 전이성 에스트로겐 수용체 양성 유방암을 치료하기 위한 에스트로겐 수용체 조절자 |
CN104693211A (zh) | 2013-12-10 | 2015-06-10 | 南京明德新药研发股份有限公司 | 作为抗病毒剂的咪唑衍生物及其制药用途 |
US9695166B2 (en) | 2014-05-05 | 2017-07-04 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
JP2017515906A (ja) | 2014-05-16 | 2017-06-15 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | 抗菌性キナゾロン−4(3h)−オン誘導体 |
CN106536520B (zh) | 2014-06-27 | 2020-08-14 | 诺格拉制药有限公司 | 芳基受体调制剂及其制备和使用方法 |
CA2964018C (en) | 2014-10-09 | 2019-04-02 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Hydroxyl purine compounds and applications thereof |
KR102559719B1 (ko) | 2014-12-18 | 2023-07-26 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
BR112017022860A2 (pt) | 2015-04-21 | 2018-07-17 | Gtx Inc | ligantes de decompostos receptores de andrógeno seletivos (sard) e métodos de utilização dos mesmos |
EP3312184A4 (en) | 2015-06-16 | 2019-02-27 | Jiangsu Hengrui Medicine Co., Ltd. | PIPERIDINE DERIVATIVE AND ITS PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF |
CN107428758B (zh) | 2015-11-12 | 2020-08-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的用途 |
RU2734501C2 (ru) | 2016-02-05 | 2020-10-19 | Инвентисбио Инк. | Селективные ингибиторы эстрогеновых рецепторов и их применение |
AU2017242027B2 (en) * | 2016-04-01 | 2020-10-08 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
CN109310664A (zh) | 2016-06-10 | 2019-02-05 | 田纳西大学研究基金会 | 选择性雄激素受体降解剂(sard)配体和其使用方法 |
EP4066827A1 (en) * | 2016-06-22 | 2022-10-05 | Ellipses Pharma Ltd | Ar+ breast cancer treatment methods |
WO2018001232A1 (zh) | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
WO2018130124A1 (zh) | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
-
2020
- 2020-08-04 BR BR112022002138A patent/BR112022002138A2/pt not_active Application Discontinuation
- 2020-08-04 EP EP20849650.5A patent/EP3993787A4/en active Pending
- 2020-08-04 KR KR1020227006821A patent/KR20220044528A/ko unknown
- 2020-08-04 JP JP2022507525A patent/JP2022543832A/ja active Pending
- 2020-08-04 AU AU2020326691A patent/AU2020326691A1/en active Pending
- 2020-08-04 WO PCT/US2020/044884 patent/WO2021026153A1/en active Application Filing
- 2020-08-04 CA CA3148221A patent/CA3148221A1/en active Pending
- 2020-08-04 CN CN202080056054.3A patent/CN114269342A/zh active Pending
- 2020-08-04 US US16/985,004 patent/US11278532B2/en active Active
- 2020-08-04 MX MX2022001149A patent/MX2022001149A/es unknown
- 2020-08-05 TW TW109126553A patent/TW202120084A/zh unknown
-
2022
- 2022-01-05 US US17/647,153 patent/US20220125769A1/en not_active Abandoned
- 2022-02-01 IL IL290280A patent/IL290280A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL290280A (en) | 2022-04-01 |
CA3148221A1 (en) | 2021-02-11 |
US20210038573A1 (en) | 2021-02-11 |
EP3993787A1 (en) | 2022-05-11 |
EP3993787A4 (en) | 2023-07-12 |
US20220125769A1 (en) | 2022-04-28 |
BR112022002138A2 (pt) | 2022-04-19 |
TW202120084A (zh) | 2021-06-01 |
AU2020326691A1 (en) | 2022-03-03 |
US11278532B2 (en) | 2022-03-22 |
KR20220044528A (ko) | 2022-04-08 |
JP2022543832A (ja) | 2022-10-14 |
WO2021026153A1 (en) | 2021-02-11 |
CN114269342A (zh) | 2022-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005924A (es) | Compuestos y metodos de uso de los mismos para el tratamiento del cancer. | |
MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
MX2019005834A (es) | Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2. | |
CR20210501A (es) | Inhibidores de la proteína tirosina fosfatasa | |
AU2012288626A8 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer | |
WO2016060443A3 (en) | Compounds and compositions for modulating egfr mutant kinase activities | |
PH12021550119A1 (en) | Pyridin-2-one compounds useful as smarca2 antagonists | |
MX2010004244A (es) | Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk). | |
MX2021001690A (es) | Indoles sustituidos y metodos de uso de los mismos. | |
MX2020009062A (es) | Piperidinil-3-(ariloxi)propanamidas y propanoatos. | |
NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
MX2019010149A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
WO2017177004A8 (en) | Tertiary amides and method of use | |
MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
WO2020106461A3 (en) | Anti-mertk antibodies and methods of use thereof | |
WO2017098051A3 (en) | Combined preparations of pkm2 modulators and hmgb1 | |
MX2022005749A (es) | Inhibidores de egfr alostericos y metodos de uso de los mismos. | |
MX2023012981A (es) | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. | |
MX2022006213A (es) | Piridinas sustituidas y metodos de uso. | |
MX2022001149A (es) | Moduladores del receptor de estrógeno para el tratamiento de mutantes. | |
PH12020551495A1 (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations | |
MX2020011453A (es) | Combinaciones para tratar el cancer. | |
MX2021012705A (es) | Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa. |